[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626928":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":41,"centralContacts":46,"locations":52,"responsibleParty":67,"collaborators":28,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":28,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":28,"enrollmentInfo":78,"targetDuration":28,"studyType":81,"phases":82,"briefSummary":73,"conditions":84,"keywords":86,"overallStatus":54,"whyStopped":28,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"JW Pharmaceutical","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental","EXPERIMENTAL","Empagliflozin\u002FMetformin + Anagliptin",[13,14],"Drug: Empagliflozin\u002FMetformin","Drug: Anagliptin",{"label":16,"type":17,"description":18,"interventionNames":19},"Active Comparator","ACTIVE_COMPARATOR","Metformin + Empagliflozin\u002FLinagliptin",[20,21],"Drug: Metformin","Drug: Empagliflozin\u002FLinagliptin",[23,29,33,37],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Empagliflozin\u002FMetformin","5\u002F500 mg, 5\u002F1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Anagliptin","100 mg, for 12 weeks (PO, BID)",[9],{"type":24,"name":34,"description":35,"armGroupLabels":36,"otherNames":28},"Metformin","500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)",[16],{"type":24,"name":38,"description":39,"armGroupLabels":40,"otherNames":28},"Empagliflozin\u002FLinagliptin","10\u002F5 mg, for 12 weeks (PO, QD)",[16],[42],{"name":43,"affiliation":44,"role":45},"Sung Rae Kim","The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator","PRINCIPAL_INVESTIGATOR",[47],{"name":48,"role":49,"phone":50,"phoneExt":28,"email":51},"Saemi Kang","CONTACT","82-2-840-6902","kangsm@jwhealthcare.com",[53],{"facility":44,"status":54,"city":55,"state":28,"zip":28,"country":56,"countryCode":28,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Seoul","South Korea",{"type":58,"coordinates":59},"Point",[60,61],126.9784,37.566,{"lat":61,"lon":60},[64],{"name":43,"role":49,"phone":65,"phoneExt":28,"email":66},"82-32-340-7013","kimsungrae@catholic.ac.kr",{"type":68,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100626928","phase-4-glycemic-variability-of-combination-therapies-in-t2dm-100626928",false,"NCT07442006","Glycemic Variability of Combination Therapies in T2DM","A Multicenter Study to Evaluate Efficacy and Safety","Inclusion Criteria:\n\n* Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg\u002Fday) and SGLT-2 inhibitor.\n\nExclusion Criteria:\n\n* History of acute or chronic metabolic acidosis\n* Moderate to severe renal impairment (eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic impairment\n* History of heart failure (NYHA Class III\u002FIV)","ALL","19 Years",{"count":79,"type":80},178,"ESTIMATED","INTERVENTIONAL",[83],"PHASE4",[85],"Type 2 Diabetes Mellitus (T2DM)",[87],"Glycemic Variability","2026-02-26",{"date":90,"type":91},"2026-03-02","ACTUAL",{"date":93,"type":91},"2025-10-29",{"date":95,"type":80},"2027-03-31",{"name":5,"class":6},1]